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A B S T R A C T
The cytokine interleukin-1b (IL-1b) is a key mediator of the inﬂammatory response. Essential for the
host-response and resistance to pathogens, it also exacerbates damage during chronic disease and acute
tissue injury. It is not surprising therefore that there is a huge level of interest in how this protein is
produced and exported from cells. However, the mechanism of IL-1b release has proven to be elusive. It
does not follow the conventional ER-Golgi route of secretion. A literature full of disparate observations
arising from numerous experimental systems, has contributed to a complicated mix of diverse proposals.
Here we summarise these observations and propose that secretion of IL-1b occurs on a continuum,
dependent upon stimulus strength and the extracellular IL-1b requirement.
 2011  Elsevier Ltd.  
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Interleukin-1b (IL-1b) is a potent pro-inﬂammatory cytokine
that is crucial for host-defence responses to infection and injury
[1]. It is also the best characterised and most studied of the 11 IL-1
family members. It is produced and secreted by a variety of cell
types although the vast majority of studies have focussed on its
production within cells of the innate immune system, such as
monocytes and macrophages. It is produced as an inactive 31 kDa
precursor, termed pro-IL-1b, in response to molecular motifs
carried by pathogens called ‘pathogen associated molecular
patterns’ (PAMPs). PAMPs act through pattern recognition* Corresponding author. Tel.: +44 0 161 275 5039; fax: +44 161 275 5948.
E-mail address: david.brough@manchester.ac.uk (D. Brough).
1359-6101  2011 Elsevier Ltd. 
doi:10.1016/j.cytogfr.2011.10.001
Open access under CC BY license.receptors (PRR’s) on macrophages to regulate pathways that
control gene expression [2]. Induction of pro-IL-1b expression is
generally referred to as a priming step, and is an inefﬁcient
secretion stimulus. The primed cell must now encounter a further
PAMP, or DAMP (danger associated molecular pattern, endogenous
molecules released from dead cells) to induce the processing and
secretion of an active IL-1b molecule.
Pro-IL-1b is cleaved by the pro-inﬂammatory protease caspase-
1 [3]. The activation of caspase-1 occurs via recruitment to a multi-
protein complex termed the inﬂammasome (Fig. 1A); a molecular
scaffold composed of adaptor molecules, a cytosolic pattern
recognition receptor, and pro-caspase-1 [4]. The best characterised
inﬂammasome, is formed by the cytosolic PRR NLRP3 [4]. NLRP3
has a tripartite structure with a PAMP/DAMP sensing C-terminal
leucine rich repeat (LRR), a central nucleotide binding (or NACHT)
domain and an N-terminal pyrin domain (PYD) [4]. The PYD
Fig. 1. Schematic diagrams showing the components and the formation of the inﬂammasome, and of the conventional pathway of protein secretion. (A) Following the
activation of a primed cell by an appropriate stimulus (see Section 3.1) a series of homotypic interactions take place between an adaptor molecule (ASC), a cytosolic PRR
(e.g. a NLR) and pro-caspase-1 to form an inﬂammasome. This results in the activation of caspase-1 and the secretion of IL-1b. (B) Conventionally secreted proteins are
translocated into the ER and trafﬁc through the ER and Golgi before reaching their extracellular destination. The fungal metabolite brefeldin A inhibits the conventional
pathway of protein secretion.
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associated speck-like protein containing a caspase recruitment
domain (ASC) via a homotypic interaction with its PYD domain.
Likewise, pro-caspase-1 is recruited to ASC via a homotypic
interaction of CARD domains facilitating caspase-1 activation.
Following caspase-1-dependent processing of pro-IL-1b, mature
IL-1b is rapidly secreted from the cell [5]. However, how IL-1b is
secreted from the cell is not clear. Multiple observations and
proposals have been made that do not allow the formation of a
single uniﬁed mechanism of secretion, but rather suggest that
there are multiple mechanisms. These of course may not be
mutually exclusive, but may each make a speciﬁc contribution to
IL-1b-dependent inﬂammation. Here, we attempt to summarise
these observations and to provide a rationale for the existence of
the multiple mechanisms proposed.
2. Conventional protein secretion
The endoplasmic reticulum (ER) and Golgi apparatus together
form the endo-membrane system responsible for the targeting of
the vast majority of proteins to the extracellular space and to
specialised sub-cellular compartments [6]. So typical is this
mechanism for protein export, it has attained the status of being
the ‘conventional’ pathway when compared to the secretion of a
handful of proteins that utilise alternative ‘non-conventional’
routes of cellular exit [7]. Typically proteins are co-translation-
ally translocated into the ER, although some are post-transla-
tionally translocated [8]. The ﬁrst step in the co-translational
pathway of translocation is the detection of a signal sequence at
the N-terminus of the nascent peptide, as it emerges from the
ribosome, by the signal recognition particle (SRP) [8,9]. The SRP
bound to the ribosome and nascent protein chain then binds tothe SRP receptor (SR) anchored on the ER membrane and
subsequently the nascent peptide chain is translocated through
the protein conducting channel formed by sec61a and sec61g
subunits into the ER lumen [8,9].
Once in the lumen of the ER the signal peptide is removed from
the nascent protein chain which then, with the aid of chaperones,
assumes a correctly folded state and accumulates at the ER exit
site by virtue of its binding to the coat protein complex II
apparatus (COPII) [10,11]. The COPII complex facilitates the
budding of COPII-coated vesicles (that contain the cargo protein)
from the ER and that subsequently fuse with the Golgi complex
thereby depositing the cargo protein for the next stage of the
secretory pathway [12]. The cargo proteins continue their journey
through the Golgi receiving further post-translational modiﬁca-
tions before they are packaged and transported to their ﬁnal
destination; another organelle, or exocytosis from the cell [13,14].
In order to maintain organelle homeostasis, and for retrieval of
proteins back to the ER, Golgi membrane needs to be recycled, and
this is achieved via the budding, retrograde transport, and fusion
of COPI coated vesicles [12]. COPI-mediated retrograde transport
is inhibited by the fungal metabolite brefeldin A (BFA), and
treatment of cells with BFA causes the collapse of the Golgi and its
redistribution into the ER, and thus completely inhibits conven-
tional protein secretion [6,15].
That, in essence, is the route taken by conventionally secreted
proteins to exit the cell (Fig. 1B). The knowledge that IL-1b lacked a
signal peptide [16] led Anna Rubartelli, in 1990, to ask whether IL-
1b utilised the conventional pathway of secretion by treating LPS-
activated monocytes with BFA. Whilst the secretion of IL-6 and
TNFa were inhibited by BFA treatment, the secretion of IL-1b was
actually enhanced, thus providing the ﬁrst direct evidence that IL-
1b follows a non-conventional route of protein secretion [17].
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3.1. Secretion stimuli
When discussing the literature on the secretion of IL-1b, it is
important to consider the stimulus inducing release. IL-1b is
released in response to many PAMPs and DAMPs which can
activate a variety, or in some cases multiple, PRR’s to form
inﬂammasomes. As discussed below, the mechanism of secretion
may be inﬂuenced by stimulus type and strength. Here we
summarise some of the best known and most widely used stimuli
that induce IL-1b secretion. Extracellular ATP acting via the P2X7
receptor induces caspase-1-dependent release of IL-1b [18,19],
and is dependent upon the formation of the NLRP3 inﬂammasome
[20]. The toxins nigericin and maitotoxin, as well as infection with
Staphylococcus aureus also induce NLRP3-dependent IL-1b release
[20]. Monosodium urate (MSU) crystals, calcium pyrophosphate
dihydrate (CPPD) crystals [21], cholesterol crystals [22], silica
crystals and aluminium salts [23], and aggregated beta-amyloid
[24] are also known activators of NLRP3. Infection of macrophages
with Salmonella typhimurium [25], Shigella ﬂexneri [26], Legionella
pneumophila [27], and Pseudomonas aeruginosa [28] all induce IL-
1b secretion via activation of an NLRC4 inﬂammasome. The NLRP1
inﬂammasome is activated by muramyl dipeptide (MDP) [29], and
in mouse, NLRP1b-inﬂammasome is activated by Bacillus anthracis
lethal toxin [30]. The DNA sensing receptors AIM2 [31,32] and RIG-
I [33] also form inﬂammasomes. Infection of macrophages with
Listeria monocytogenes induces the activation of caspase-1 via
NLRP3, NLRC4 and AIM2 inﬂammasomes [34].
3.2. Secretion mechanisms
3.2.1. Rescue and redirect
Prior to Rubartelli’s observations in 1990, it was known that IL-
1b is expressed as a precursor and that it lacks a signal sequence
[16], and also, that it is absent from the ER and the Golgi of LPS-
activated monocytes as determined by immunoelectron micros-
copy [35]. IL-1b is translated on free polyribosomes associated
with the cytoskeleton, and not membrane-bound polyribosomes
[36]. The vast majority of IL-1b in LPS-activated monocytes
localises to the cytosol, although a fraction resides in vesicles and is
protected from tryptic digestion [17,37]. These IL-1b-containing
vesicles were subsequently identiﬁed as being of endolysosomal in
nature [38]. It was proposed that a fraction of cellular IL-1b is
targeted to lysosomes for degradation, but that this fraction can be
rescued by triggering lysosome exocytosis and thus secretion of IL-
1b. Indeed, co-incubation of LPS-stimulated monocytes with the
protease inhibitors pepstatin and leupeptin enhances the release of
IL-1b supporting this hypothesis [38]. How does cytosolic IL-1b
get sequestered into vesicles? In 1990 Rubartelli suggested
autophagy may provide a route [17] and recent studies suggest
that this may in fact be the case [39]. Autophagy is a mechanism
whereby damaged organelles or proteins in the cytosol become
enclosed in a double membrane structure forming an autophago-
some. These vesicles subsequently fuse with lysosomes forming
autolysosomes resulting in the proteolytic degradation of their
contents [40]. LPS treatment of macrophages induces the recruit-
ment of IL-1b to autophagosomes. When autophagy is inhibited
this IL-1b is secreted; when autophagy is activated the seques-
tered IL-1b is degraded [39]. Thus a fraction of cellular IL-1b
targeted for degradation can be rescued and redirected to the
extracellular environment.
3.2.2. Protected release
Another route that a fraction of cellular IL-1b can take out of the
cell is via the shedding of microvesicles from the plasmamembrane [41]. This was originally observed in P2X7-receptor-
stimulated LPS-treated THP-1 cells [41], and thrombin activated
platelets [42]. In THP-1 cells shedding of IL-1b-containing
microvesicles is preceded by ﬂip of the lipid phosphatidyl serine
(PS) to the outer leaﬂet of the plasma membrane [41], and in
astrocytes requires the activation of acid sphingomyelinase [43].
The IL-1b contained in shed microvesicles is bioactive and may be
released following contact with IL-1 receptor (IL-1RI) expressing
cells [41]. IL-1b-containing microvesicles have also been isolated
from P2X7-receptor-stimulated LPS-treated microglia [44], astro-
cytes [43], and dendritic cells [45]. Shed microvesicles from
dendritic cells, containing IL-1b and caspase-1, express P2X7-
receptors in their membrane. ATP-stimulation of these micro-
vesicles induces the release of their contents and thus provides a
mechanism for how this protected IL-1b can be released at target
sites to elicit cellular responses [45].
IL-1b can also be secreted in a protected form by being
packaged and secreted via exosomes [46]. Exosomes are small
vesicles (50–80 nm vs. 100–600 nm for microvesicles [47]) that are
secreted from multi-vesicular bodies (MVB’s) or late endosomes.
They are formed by the inward budding of the MVB membrane and
contain cytosol [48]. Thus cytosolic IL-1b could be sorted into the
forming exosome via sorting protein complexes, although this has
yet to be shown. The secretion of exosomes following P2X7-
receptor stimulation of LPS-treated macrophages is dependent
upon ASC and NLRP3, but independent of caspase-1 [47]. What is
the function of protected IL-1b? The fact that much of the IL-1b
secreted from the cell appears to be directly available (see below),
and that IL-1b has a very short half life in plasma [49], suggests
that protected IL-1b is destined for signalling processes at sites
distant to the local inﬂammatory lesion. Both shed microvesicles
and exosomes from antigen presenting cells contain MHC II
molecules and induce immunomodulatory effects [50]. Thus IL-1b
could modulate immune responses induced by MHC II antigenic
peptides carried by these vesicles.
3.2.3. Terminal release
A consequence of caspase-1 activation in macrophages follow-
ing infection by NLRC4-activating pathogenic bacteria (see Section
3.1) is a rapid, and caspase-1-dependent cell death called
pyroptosis [51]. Pyroptosis is a pro-inﬂammatory form of cell
death that causes an infected macrophage to kill itself, and at the
same time release pro-inﬂammatory cytokines such as IL-1b and
another caspase-1 substrate IL-18 [51]. The rapid caspase-1-
dependent pyroptotic cell death caused by S. typhimurium [52], as
well as the caspase-1-dependent clearance of NLRC4-activating
pathogens in vivo [53] do not depend upon IL-1b processing,
although that does occur. It seems that pyroptosis serves
principally to eliminate the intracellular niche required for
pathogen growth [54]. Pyroptosis of macrophages following
infection with S. typhimurium occurs after the caspase-1-depen-
dent formation of pores (1.1–2.4 nm in diameter) in the plasma
membrane [55]. These pores cause the dissipitation of ionic
gradients and the osmotic lysis of the cell. This osmotic lysis can be
inhibited by the presence of glycine, yet pore formation and IL-1b
release is not blocked [55]. These caspase-1-dependent pores may
provide a conduit through which IL-1b passes to reach the
extracellular space [51,55].
However, cell death associated with IL-1b release is not only
dependent upon infection with NLRC4-activating pathogens. Over
20 years ago it was reported that stimulation of LPS-primed
peritoneal macrophages with ATP or allospeciﬁc cytotoxic T-
lymphocytes induces cell death in addition to IL-1b processing
and release [56]. 30 min incubation with the NLRP3-activating
stimulus ATP causes LPS-primed murine peritoneal macrophages
to round up and bleb, which is closely followed by the release of
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release of mature IL-1b precedes release of LDH [5,57,58], is does
raise the suggestion that IL-1b release signals a commitment to
cell death [59]. ATP-induced death of LPS-treated mouse
peritoneal macrophages is caspase-1-dependent [19]. Incubation
of macrophages with glycine inhibits ATP-induced cell lysis, but
not the release of mature IL-1b [60], similar to the phenomenon
observed following S. typhimurium infection described above [55].
In LPS-activated monocytes treated with the NLRP3-activating
stimuli, heat killed S. aureus, caspase-1 and IL-1b localise to the
plasma membrane, prompting the suggestion that caspase-1 may
gate a membrane pore through which IL-1b transits [61]. Bone
marrow derived macrophages transduced to express the IL-1
family member IL-36a, and a non-cytokine Green Fluorescence
Protein (GFP), when stimulated with LPS and ATP release IL-1b, IL-
36a and GFP in parallel, suggesting release is due to a change in
membrane integrity [62]. Thus, there are many similarities
between NLRC4-mediated pyroptosis and NLRP3-mediated cell
death following P2X7-receptor stimulation. The mechanisms of
release described in the previous sections however are reported to
be non-cytolytic (see Sections 3.2.1 and 3.2.2) even though the use
of ATP as a secretion stimulus is common. The possible reasons for
the differences in IL-1b release and commitment to cell death are
discussed in detail below.
Cell lysis per se does not automatically induce release of
processed IL-1b. LPS-stimulated murine peritoneal macrophages
release exclusively pro-IL-1b when injured by scraping, excessive
heat, freeze thaw or oxidative injury by H2O2 treatment [56].
Likewise, when treated with the Ca2+ ionophore A23187, or the
detergent saponin, unprocessed pro-IL-1b is the only form of IL-1
found extracellularly [58]. Although not biologically active, the
release of pro-IL-1b following necrotic cell death may not be
without relevance. In models of sterile tissue injury [63] and acuteFig. 2. The continuum of IL-1b secretion. The secretion of IL-1b is reported to occur v
continuum. The mechanism recruited may be dependent upon the strength of the inﬂam
Rescue and redirect, protected release and terminal release.arthritis [64,65], a caspase-1-independent activation of IL-1b is
reported. A number of neutrophil derived proteases are known to
cleave pro-IL-1b into biologically active molecules [63,66], with a
demonstrated role for proteinase 3 in acute arthritis [64]. Thus,
released pro-IL-1b following tissue injury and cell necrosis could
be cleaved extracellularly by proteases derived from inﬁltrating
neutrophils resulting in an IL-1b-dependent inﬂammatory re-
sponse independent of caspase-1. Pro-IL-1b can also be processed
into biologically active molecules by proteases from S. aureus [67]
and Candida albicans [68] suggesting that extracellular processing
may also occur at inﬂammatory lesions caused by infection.
4. Spectrum of secretion
Cell type, species, source and concentration of PAMPs and
DAMPs, not to mention their nature and the duration of the
stimulation are all factors that introduce variation and that may
account for the predominance of one mechanism of secretion over
another in many of the studies discussed above. Other important
factors are likely to include the cells microenvironment, where
temperature and pH [69], redox balance [70,71], osmolarity [72],
culture conditions and time in culture [73] inﬂuence IL-1b release,
as does the polarisation state of the macrophage (i.e. M1-M2) [74].
Thus the strength of the inﬂammatory input as perceived by the
cell may vary widely from one study to another. It may thus be
possible to view the different observations on the mechanisms of
IL-1b secretion as belonging to a spectrum, or continuum, of
release (Fig. 2). Depending upon the inﬂuencing factors described
above, a cell may be induced to release a low level of IL-1b without
a commitment to cell death. As the inﬂammatory insult escalates
more mechanisms become engaged or employed to the extent that
the cell can no longer maintain the latency of the plasma
membrane and a commitment to cell death results. For example,ia a number of mechanisms. This ﬁgure illustrates these mechanisms as part of a
matory stimulus as perceived by the cell. The secretion mechanisms are classiﬁed as
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mechanism for the release of IL-1b, although it is followed by a
slower, non-protected release of IL-1b from the cell [41]. Following
ATP-induced P2X7 receptor activation on macrophages and
dendritic cells both exosomes and shed microvesicles are detected
in the culture supernatant [47]. Lysosome exocytosis during
pyroptosis does occur, although in this case is suggested as an
attempt by the cell to repair caspase-1-dependent membrane
pores rather than as a mechanism of cytokine secretion [75]. These
studies suggest that multiple mechanisms may be engaged for the
release of IL-1b within the same cell population.
5. Inhibiting secretion
Although essential for resistance to infections, IL-1b also
exacerbates damage during chronic disease and acute tissue
injuries [76]. Thus the release mechanisms of IL-1b represent a
therapeutic target. ATP-induced IL-1b release is abolished in
macrophages isolated from caspase-1 KO mice [77]. Given that
processing and secretion are thus so closely coupled, perhaps the
most effective way of inhibiting IL-1b release is by inhibiting
caspase-1. Peptide inhibitors corresponding to the cleavage site on
IL-1 (YVAD) [3] are effective and widely used inhibitors of caspase-
1, and block release of IL-1b [78]. Indirect inhibitors of caspase-1
are also effective. The sulfonyl urea drug glyburide, and related
sulfonyl ureas inhibit ATP-induced IL-1b release [79] by inhibiting
the NLRP3 inﬂammasome [80]. Glyburide also inhibits the
accumulation of IL-1b into secretory lysosomes [38]. Lysosomal
membrane rupture and cathepsin B activity are important for the
activation of the NLRP3 inﬂammasome in response to some
stimuli, where inhibition of cathepsin B attenuates IL-1b release
[23,24]. In the past many diverse pharmacological effectors such as
the phospholipase inhibitor bromoenol lactone [81,82], the protein
phosphatase inhibitor okadaic acid and hypertonic buffer [72],
anion transport inhibitors [83], alkylating agents [59], redox active
drugs [70], histone deacetylase inhibitors [84], acid sphingomye-
linase inhibitors [43], have been reported to inhibit IL-1b release.
Given that the mechanisms of action and targets of many of these
drugs remain unclear there is great potential for further discovery
and exploitation of this pathway.
6. Conclusions and future perspectives
IL-1b is a potent pro-inﬂammatory cytokine produced by cells
of the innate immune system. It is produced without a signal
sequence and does not follow the conventional route of protein
secretion, but rather employs one or more non-conventional
pathways of secretion. In an attempt to consolidate the many
disparate observations on IL-1b release from the literature, and
to provide a rationale for their existence, we have suggested that
all mechanisms are part of one continuum of secretion, or a
spectrum (Fig. 2), where the routes of secretion employed are
dictated by the strength of the inﬂammatory stimulus and thus
the levels of IL-1b required extracellularly to mount an effective
inﬂammatory response. We propose that there are, in general,
three categories of secretion mechanism. For their classiﬁcation
in this review we have labelled them as Rescue and redirect,
protected release and terminal release. We discuss evidence to
suggest that more than one of these mechanisms can be engaged
within the same cell population at any one time adding credence
to our proposal.
Rescue and redirect is based on Rubartelli’s observation that there
is a fraction of cellular IL-1b localised to vesicles of endolysosomal
nature that is targeted for degradation, but that can be redirected to
the extracellular space following an appropriate secretion stimulus
[38]. The regulated secretion of lysosomes is crucial for cells ofhemopoietic linage and can occur in response to a variety of stimuli
[85]. It is non-lytic and given that only a small fraction of cellular IL-
1b is localised to vesicles [17], such a mechanism will likely be
engaged when the extracellular requirement for IL-1b is low, or
perhaps to supplement extracellular IL-1b provided by other
mechanisms. Protected release is based upon, ﬁrstly the observation
that bioactive IL-1b can be found in shed microvesicles from the
plasma membrane [41], and subsequently that it is also found in
secreted exosomes [46]. Since IL-1b has a very short half life in
plasma, it makes sense to suggest that protected IL-1b is destined for
sites distant to the inﬂammatory lesion. In ATP stimulated THP-1
cells there is, in addition to microvesicle contained IL-1b, vesicle free
IL-1b released into the supernatant [41]. Thus, protected release
occurs alongside additional mechanisms providing locally available
IL-1b. Terminal release involves a commitment to cell death and
occurs, we propose, under conditions of extreme inﬂammatory
stress. Such a mechanism seems geared for the rapid release of large
quantities of active IL-1b directly across a disintegrating plasma
membrane. It may be possible not to exceed a threshold of plasma
membrane latency before the commitment to cell death becomes
irreversible.
Due to the diversity of secretion stimuli, culture conditions, the
cell types that secrete IL-1b and the difﬁculty of their genetic
manipulation, elucidating the precise mechanisms of IL-1b
secretion remains a considerable challenge. By viewing the non-
conventional secretion of IL-1b as a continuum dependent upon
the extracellular requirement of IL-1b, it has been possible to
rationalise a context in which all mechanisms contribute to the
secretion of IL-1b. Given that there is still so much biology to be
discovered about IL-1b and that there is a collective curiosity
within the ﬁeld about how its released, the picture of IL-1b release
mechanisms is likely to be dynamic with many future insights yet
to come.
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